Progression of fibrosis in liver transplant recipients with hepatitis C before and after sustained virologic response
- 17 June 2023
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 37 (10) , e15050
Abstract
Background: Liver transplant (LT) recipients with untreated hepatitis C (HCV) are at risk for cirrhosis graft failure. The advent of direct acting antiviral agents (DAA) has improved outcomes in HCV.Aims: We aim to examine liver transplant outcomes and allograft fibrosis development/progression after sustained virologic response (SVR).Methods: We performed a retrospective cohort study of 226 consecutive liver transplant recipients with HCV from 2007 to 2018. The cohort was split into transplants pre (Group A) and post (Group B) 2014 to reflect the introduction of DAAs. Fibrosis was monitored with liver biopsy and non‐invasive imaging.Results: Group B had significantly improved HCV treatment rates and earlier SVR compared to Group A, with a cumulative incidence rate of SVR at 2 years of 86.7% versus 15.4% (HR = .11, p < .001). Prior to achieving SVR, Group A demonstrated worsening of fibrosis stage per year (+.21, p < .001) whereas Group B showed minimal change on protocol annual biopsy (−.02, p = .80). After SVR, most patients were followed non‐invasively and demonstrated stable or improved fibrosis stage over time. Patients undergoing transient elastography showed regression in fibrosis stage per year (−.19, p < .001).Conclusion: HCV patients undergoing LT after 2014 had higher rates of SVR and improved clinically relevant transplant outcomes, namely less graft loss and death relating to HCV. Fibrosis progression halted or improved after SVR in both cohorts, suggesting that LT recipients with SVR do not require fibrosis monitoring even with established fibrosis prior to SVR.Keywords
This publication has 9 references indexed in Scilit:
- Non‐invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)‐associated liver disease and sustained virologic response (SVR): 3 years follow‐up of a prospective longitudinal studyJournal of Viral Hepatitis, 2021
- Lower Likelihood of Post-transplant Graft Failure, Death, and Retransplantation in the Era of Direct-Acting AntiviralsJournal of Clinical and Experimental Hepatology, 2020
- Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining ChallengesGastroenterology, 2019
- Efficacy of Direct-acting Antivirals to Improve Clinical Condition, Fibrosis, and Liver Function in Liver Transplant Recipients Infected by Hepatitis CTransplantation Proceedings, 2019
- The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list compositionJournal of Hepatology, 2018
- Improved Outcomes in HCV Patients Following Liver Transplantation During the Era of Direct-Acting Antiviral AgentsClinical Gastroenterology and Hepatology, 2018
- Liver transplantation for chronic hepatitis C virus infection in the United States 2002–2014: An analysis of the UNOS/OPTN registryPLOS ONE, 2017
- Ultrasound-Based Transient Elastography for the Detection of Hepatic Fibrosis in Patients With Recurrent Hepatitis C Virus After Liver Transplantation: A Systematic Review and Meta-AnalysisLiver Transplantation, 2012
- Long-Term Outcome of Hepatitis C Infection after Liver TransplantationNew England Journal of Medicine, 1996